Navigation Links
Nile Therapeutics Reports 2012 First Quarter Financial Results
Date:5/15/2012

SAN FRANCISCO, May 15, 2012 /PRNewswire/ -- Nile Therapeutics, Inc. (OTCQB: NLTX), a biopharmaceutical company that develops novel therapeutics for heart failure patients, today announced its first quarter financial results for 2012. 

For the first quarter of 2012, Nile reported a net operating loss of $0.8 million, or $0.02 per share. Weighted-average shares outstanding for the quarter were 39.7 million. Nile reported collaboration income of $0.2 million during the quarter ended March 31, 2012.

As of March 31, 2012, Nile had cash and cash equivalents of $0.4 million compared to $1.0 million as of December 31, 2011. On March 30, 2012, Nile entered into definitive agreements to sell shares of its common stock and warrants in a registered direct offering. Net proceeds of the offering were approximately $1.1 million.About Nile TherapeuticsNile Therapeutics, Inc. is a clinical-stage biopharmaceutical company that develops innovative products for the treatment of cardiovascular disease and other areas of unmet medical needs. Nile is initially focusing its efforts on developing its lead compound, cenderitide, a novel rationally designed chimeric peptide in clinical studies for the treatment of heart failure. More information on Nile can be found at http://www.nilethera.com

Safe Harbor Paragraph for Forward-Looking Statements: This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that involve substantial risks and uncertainties. All statements, other than statements of historical facts, included in this press release regarding Nile's plans to develop cenderitide in the post-acute setting and the anticipated benefits of cenderitide for patients in the post-acute setting are forward-looking statements. Nile may not actually achieve these plans, intentions or expectations and Nile cautions investors not to place undue reliance on Nile's forward-looking statements. Actual results or events could differ materially from the plans, intentions and expectations disclosed in the forward-looking statements Nile makes. Various important factors that could cause actual results or events to differ materially from the forward-looking statements that Nile makes include Nile's immediate need to raise additional capital to fund its general corporate activities and its need to raise substantial additional capital to fund its planned Phase 2 study of cenderitide and to otherwise fund its product development programs to completion, Nile's reliance on third-party researchers to develop its product candidates, and its lack of experience in developing and commercializing pharmaceutical products. Additional risks are described in greater detail in the reports Nile files with Securities and Exchange Commission, including those described under the caption "Risk Factors" in Item 1A of its Annual Report on Form 10-K for the year ended December 31, 2011 filed with the Securities and Exchange Commission on April 2, 2012. Nile is providing this information as of the date of this press release and does not undertake any obligation to update any forward-looking statements as a result of new information, future events or otherwise.Condensed Statement of OperationsThree months ended March 31,20122011Income:Collaboration income$
95,500$
-Operating expenses:Research and development465,353622,332General and administrative500,020575,278Total operating expenses965,3731,197,610Loss from operations(769,873)(1,197,610)Other income (expense):Interest income2441,986Other income (expense)(2,250)(168)Total other income (expense) (2,006)1,818Net loss$
(771,879)$
(1,195,792)Basic and diluted loss per share$
(0.02)$
(0.03)Weighted-average common shares outstanding39,712,23134,673,475Summary Balance Sheet(in thousands)March 31,  2012December 31, 2011Cash and cash equivalents $
436$   1,039Working Capital$
71$
769Stockholders' equity$
231$
831


'/>"/>
SOURCE Nile Therapeutics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
2. Allos Therapeutics Initiates Study of PDX in Patients with Cutaneous T-Cell Lymphoma
3. Amicus Therapeutics Announces Second Quarter 2007 Financial Results
4. TorreyPines Therapeutics Completes Patient Enrollment in Phase IIb Clinical Trial of Tezampanel for the Treatment of Acute Migraine Headache
5. CV Therapeutics Announces Eight Abstracts Accepted for Presentation at the European Society of Cardiology Congress 2007
6. Pharmacopeia Assists the World Health Organization in the Discovery of Novel Therapeutics for the Treatment of Malaria
7. Protalix BioTherapeutics Treats First Patient in Phase III Clinical Trial of prGCD
8. TorreyPines Therapeutics Initiates a Phase I Multiple Dose Clinical Trial of Tezampanel
9. TorreyPines Therapeutics Completes Phase I Multiple Dose Clinical Trial of NGX267, a Selective M1 Agonist for the Potential Treatment of Cognitive Impairment Associated with Schizophrenia
10. Cell Therapeutics, Inc. (CTI) Launches Phase III Study for Pixantrone in Relapsed Indolent Non-Hodgkins Lymphoma (NHL)
11. Cell Therapeutics, Inc. (CTI) Sponsors Panel Discussion on Women and Lung Cancer on Capitol Hill
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/18/2017)... 17, 2017  Bayer announced today that the latest ... presented at the 53 rd Annual Meeting of ... June 2-6 in Chicago . ... prostate, colorectal, liver and thyroid cancers, as well as ... II CHRONOS-1 trial of copanlisib in patients with relapsed ...
(Date:5/15/2017)... Inc., a privately-held CNS pharmaceutical company based in ... disease (PD), has enrolled the first patient in the RASMET ... study involving patients with PD and taking place at 12 ... period. The first stage is open label and involves single ... Denver , Boca Raton ...
(Date:5/11/2017)... TORONTO , May 11, 2017  Thornhill ... ) has been awarded an $8,049,024 USD five-year, ... Defense through the Canadian Commercial Corporation (CCC) ( ... Field Anesthesia Systems to administer general anesthesia to ... environment.  "The US Marine Corps have ...
Breaking Medicine Technology:
(Date:5/26/2017)... ... ... “Cactus Jack: Against All Odds”: the story of Coach Cactus Jack and the impact ... the creation of published author, Walter Hubbard, a retired wildlife and fisheries biologist and ... Walter. Walter and Jane have three adult children and a granddaughter. Walter ...
(Date:5/24/2017)... ... May 24, 2017 , ... Last month, representatives ... hospital employees, and town officials to celebrate the grand opening of the 87,000 ... Rendina as part of its ongoing relationship with RWJBarnabas Health, New Jersey’s largest ...
(Date:5/24/2017)... ... 2017 , ... Dr. Alan I. Benvenisty, MD is dual board certified in ... known for his distinguished expertise and experience in the diagnosis and treatment of vascular ... treating renovascular disease and aortic aneurysm . He is known for his minimally ...
(Date:5/24/2017)... ... May 24, 2017 , ... ... management and interpretation, has received U.S. Food and Drug Administration (FDA) 510(k) ... web-based, scalable and secure cloud platform for medical image management. At the core ...
(Date:5/24/2017)... Cincinnati, OH (PRWEB) , ... May 24, 2017 , ... ... discreet and comfortable ClearCorrect orthodontics, with or without a referral. Dr. Kejriwal ... is why she offers convenient, clear braces in Cincinnati, OH. Patients no longer need ...
Breaking Medicine News(10 mins):